Gaál-Weisinger Júlia, Mucsi Orsolya, Körösmezey Gábor, Szili Balázs, Eid Hanna, Kiss Richárd, Bödör Csaba, Tárkányi Ilona, Nagy Zsolt, Demeter Judit
I. Sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary.
I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, Budapest, Hungary.
Magy Onkol. 2017 Mar 8;61(1):67-74. Epub 2017 Feb 3.
The introduction of tyrosine kinase inhibitor (TKI) treatment has resulted in dramatically improved survival in chronic myeloid leukemia (CML). With the new generation of TKIs the majority of patients reach optimal molecular response. Due to the improving survival and the need for lifelong treatment, the safety profile of the various TKIs and the comorbidities of patients have to be considered. More than half of our CML patients had comorbidities that could have influenced the choice of therapy. Because of the high prevalence of cardiovascular comorbidities, cardiovascular risk assessment plays an important role in the care of CML patients. The aim of this article is to summarize the current national and international guidelines of the treatment in CML and to show the importance of comorbidities and cardiovascular risk assessment in our CML patients.
酪氨酸激酶抑制剂（TKI）治疗的引入显著提高了慢性髓性白血病（CML）患者的生存率。随着新一代TKI的出现，大多数患者达到了最佳分子反应。由于生存率的提高以及终身治疗的需求，必须考虑各种TKI的安全性以及患者的合并症。我们超过一半的CML患者患有可能影响治疗选择的合并症。由于心血管合并症的高患病率，心血管风险评估在CML患者的护理中起着重要作用。本文的目的是总结当前国内和国际上CML治疗指南，并展示合并症和心血管风险评估在我们CML患者中的重要性。
